Expansion of Cancer Risk Profile beyond Breast and Ovarian Cancer for BRCA1 and BRCA2 Pathogenic Variants
Segmentectomy versus Lobectomy in Small-Sized Peripheral Non-Small Cell Lung Cancer
FDA Grants Regular Approval to ENHERTU® for Breast Cancer
Lower Gastrointestinal Endoscopy before Age 50 Years Reduces Risk for Colorectal Cancer among Women
Risk of Coagulopathy Persists for Several Months after COVID-19
DARZALEX® plus KYPROLIS® and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Investigator and Health Systems Insights on Real-World Evidence Associated With a First-Generation BTK Inhibitor in Patients With CLL/SLL
Lung Cancer Screening with Low Dose CT Associated with Favorable Stage Shift and Improved Survival
TIBSOVO® and VIDAZA® Combo Improve Survival in IDH1-Mutated Acute Myeloid Leukemia
Overall Survival at 2 Years with LUMAKRAS® for KRAS G12C Positive Non Small Cell Lung Cancer
Genetically Adjusted PSA Values May Improve the Accuracy of Prostate Cancer Detection
OPDIVO® (nivolumab) + chemotherapy (fluoropyrimidine + platinum-based) for the first-line (1L) treatment of metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma, regardless of PD-L1 status
TUKYSA® in Pretreated HER2-positive Metastatic Breast Cancer With and Without Brain Metastases: Final Overall Survival Analysis
Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test
FDA Approves Neoadjuvant OPDIVO® and Chemotherapy Combination for Early Stage Non Small Cell Lung Cancer
FDA Approves YESCARTA® for Second Line Treatment of Large B-cell Lymphoma
FDA Approves PSMA Targeted Therapy for Metastatic Castrate Resistant Prostate Cancer
FDA Approves Single Agent KEYTRUDA® for Advanced Endometrial Carcinoma
KISQALI® Plus FEMARA® Improves Overall Survival in Advanced Breast Cancer
FDA Approves LAG-3 Inhibitor OPDUALAG® and OPVIDO® in Advanced Untreated Melanoma
Bottom Ad
Advertisement
Subscribe
